文献速递关节外科

翻修髋膝关节置换中假体成本占医保报销比例大

Implant Costs Consume a Large Proportion of the Reimbursement in Revision Hip and Knee Arthroplasties.
PubMed 文献 · J Arthroplasty · 2026-02-06

该研究回顾性分析了单中心199例翻修全髋关节置换(rTHA)和187例翻修全膝关节置换(rTKA),评估假体成本占诊断相关组(DRG)报销的比例及变异性。结果显示假体成本平均占DRG 466报销的24%、DRG 467的36.7%、DRG 468的35%,且rTKA假体成本占比显著高于rTHA(33.3% vs 25.7%,P < 0.001)。

要点

  • 翻修关节置换中假体成本占DRG报销的较大比例,平均24%–36.7%。
  • rTKA假体成本占报销比例显著高于rTHA(33.3% vs 25.7%,P < 0.001)。
  • 同一关节既往手术次数多和ASA评分≥3与假体成本升高相关。

核心结论

  • 翻修关节置换中假体成本消耗了DRG报销的很大一部分,且成本决定因素变异大,DRG系统难以反映翻修全关节置换的复杂性和成本变异性。

研究设计与样本

  • 回顾性连续病例系列,纳入2019年6月1日至2021年6月1日单中心199例rTHA和187例rTKA,分析DRG 466、467、468的假体成本与报销数据。

主要发现

  • 假体成本平均占DRG 466报销的24%(范围2.4–133)、DRG 467的36.7%(范围3.5–118)、DRG 468的35%(范围2.5–175)。
  • 按诊断分层,假体成本占报销比例范围最大的组为无菌性松动(6.6–178.2)、感染(3.2–129.3)和金属沉着病(2.4–108.6%)。
  • rTKA假体成本占总体报销比例显著高于rTHA(33.3% vs 25.7%,P < 0.001)。
  • 同一关节既往关节置换手术次数更多(P < 0.001)和ASA评分≥3(P = 0.006)与假体成本升高相关。

临床怎么用

  • 在翻修关节置换的DRG付费管理中,应关注假体成本占比高且变异大的问题,尤其是rTKA、多次翻修及高ASA评分患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revision total hip arthroplasty (rTHA) and revision total knee arthroplasty (rTKA) burdens continue to increase while overall reimbursement decreases. We sought to evaluate the percentage and variability of the diagnosis-related group (DRG) reimbursement spent on implants in revision arthroplasty. METHODS: A consecutive series of 199 rTHAs and 187 rTKAs performed between June 1, 2019, and June 1, 2021, was reviewed at one academic medical center. Patient characteristics, preoperative diagnosis, implant records, and billing data were recorded for DRG 466 (revision hip or knee arthroplasty with major complication), 467 (revision with complication or comorbidity), and 468 (revision without comorbidity or complication). Data were stratified by DRG and diagnosis. Implant, surgery type, and patient comorbidity factors were analyzed for association with increased costs. RESULTS: Implant costs comprised an average of 24% of reimbursements for DRG 466 (range, 2.4 to 133), 36.7% for DRG 467 (range, 3.5 to 118), and 35% for DRG 468 (range, 2.5 to 175). When stratified by diagnoses, groups with the largest ranges in implant costs as a percentage of the reimbursement were aseptic loosening (range, 6.6 to 178.2), infection (range, 3.2 to 129.3), and metallosis (range, 2.4 to 108.6%). Implants for rTKA were significantly more of the overall reimbursement than rTHA across all DRGs (33.3 versus 25.7%, P < 0.001). Factors associated with higher implant costs included more prior arthroplasty surgeries on the same joint (P < 0.001) and an American Society of Anesthesiologists (ASA) score of ≥ 3 (P = 0.006). CONCLUSIONS: A major portion of the DRG reimbursement is spent on implants in revision arthroplasty. However, there is a wide range in cost determinants, making it difficult to determine the profitability associated with individual diagnoses. Our findings highlight the limited ability of the DRG system to capture the complexity and variability of costs in revision total joint arthroplasty (rTJA).

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. SmithOram AL, Mears SC, Barnes CL, et al. Implant Costs Consume a Large Proportion of the Reimbursement in Revision Hip and Knee Arthroplasties. J Arthroplasty. 2026. PMID: 41655720. doi:10.1016/j.arth.2026.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。